178238-83-0

Upstream product

• 178239-09-3 (E)-3-methoxy-4-(2-phenyl-4-oxazolylmethoxy)cinnamaldehyde 
• 369-34-6 3,4-difluoronitrobenzene 
• 70502-03-3 [5-methyl-2-phenyl-1,3-oxazol-4-yl]methanol 
• 178238-76-1 (E)-3-[3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]-2-propen-1-ol 
• 178239-22-0 methyl 2-bromo-3-[3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]propionate 
• 178610-65-6 methyl (E)-3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)cinnamate 
• 178610-64-5 3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)aniline 

Downstream Products

• 421558-49-8 5-[3-fluoro-4-(5-methyl-2-phenyl-4-oxazolylmethoxy)phenyl]valeronitrile 

Relevant academic research and scientific papers

Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents.

A series of 5-(4-alkoxyphenylalkyl)-1H-tetrazole derivatives, containing an oxazole-based group at the alkoxy moiety, was prepared and their antidiabetic effects were evaluated in two genetically obese and diabetic animal models, KKAy mice and Wistar fatt

Oxazolidinedione derivatives, their production and use

2,4-Oxazolidinedione derivative represented by the formula: STR1 wherein R stands for an optionally substituted hydrocarbon residue or heterocyclic group; Y stands for a group represented by --CO--, --CH(OH)-- or --NR3 -- (wherein R3 stands for an optionally substituted alkyl group); m is 0 or 1; n is 0, 1 or 2; A stands for a C1-7 divalent aliphatic hydrocarbon group; R1 stands for hydrogen or an alkyl group; ring E stands for a benzene ring having 1 or 2 substituents; L and M respectively stand for hydrogen, or L and M may optionally be combined with each other to form a bond; with a proviso that the partial formula: STR2 does not include the formula: STR3 wherein R' stands for an alkyl group; or a salt thereof, which has excellent actions of lowering blood sugar and lipid in blood.